Paul Rickey - Alpine Immune CFO, Senior Vice President Secretary
| ALPNDelisted Stock | USD 12.37 0.23 1.83% |
President
Mr. Paul Rickey, CPA. serves as Chief Financial Officer, Senior Vice President of the company. He has served as our senior vice president and chief financial officer since the completion of the Merger in July 2017 and previously served as Private Alpines senior vice president and chief financial officer since April 2017. Mr. Rickey is an experienced executive who has spent over 16 years guiding financial strategy in the life sciences and technology industries. Prior to his joining Private Alpine in 2017, Mr. Rickey served as chief financial officer of Sound Pharmaceuticals, overseeing finance, accounting and human resources. Before joining Sound Pharmaceuticals in 2016, Mr. Rickey was vice president of finance and administration of Immune Design Corporationration, a publicly traded biotechnology company, where he helped complete the companys private offerings, initial public offering, and followon financing, and also oversaw the corporate development, accounting and human resource functions. Before joining Immune Design in 2009, Mr. Rickey was corporate controller of Northstar Neuroscience, a publiclytraded medical device company, where he managed the companys finance and accounting groups following Northstars initial public offering. Prior to his role at Northstar Neuroscience, Mr. Rickey was the accounting manager for Mobliss, Inc., a mobile technology company that was sold to Index Corporationration, of Japan. Mr. Rickey started his finance career at Ernst Young LLP since 2017.
| Age | 45 |
| Tenure | 7 years |
| Phone | 206 788 4545 |
| Web | https://www.alpineimmunesciences.com |
Alpine Immune Management Efficiency
The company has return on total asset (ROA) of (0.101) % which means that it has lost $0.101 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1467) %, meaning that it created substantial loss on money invested by shareholders. Alpine Immune's management efficiency ratios could be used to measure how well Alpine Immune manages its routine affairs as well as how well it operates its assets and liabilities.Alpine Immune Sciences currently holds 9.91 M in liabilities with Debt to Equity (D/E) ratio of 0.17, which may suggest the company is not taking enough advantage from borrowing. Alpine Immune Sciences has a current ratio of 2.7, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Alpine Immune's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 5 records | PRESIDENT Age | ||
| James Doherty | Acumen Pharmaceuticals | 56 | |
| Erin MD | Terns Pharmaceuticals | 53 | |
| Lee MBA | Bicycle Therapeutics | 43 | |
| Kelly Carranza | Acumen Pharmaceuticals | N/A | |
| Mary MD | IGM Biosciences | 59 | |
Management Performance
| Return On Equity | -0.15 | |||
| Return On Asset | -0.1 |
Alpine Immune Sciences Leadership Team
Elected by the shareholders, the Alpine Immune's board of directors comprises two types of representatives: Alpine Immune inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alpine. The board's role is to monitor Alpine Immune's management team and ensure that shareholders' interests are well served. Alpine Immune's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alpine Immune's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Temre Johnson, Head Communications | ||
| Remy Durand, Chief Officer | ||
| Andrew MD, Chief Officer | ||
| Paul Rickey, CFO, Senior Vice President Secretary | ||
| Stanford MD, President Development | ||
| Wayne Gombotz, Chief Officer | ||
| Mitchell MD, Executive CEO | ||
| Pamela Holland, VP Research | ||
| Wolfgang MD, Chief Officer | ||
| Christina Yi, Chief Officer |
Alpine Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alpine Immune a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.15 | |||
| Return On Asset | -0.1 | |||
| Profit Margin | (0.65) % | |||
| Operating Margin | (3.23) % | |||
| Current Valuation | 4.16 B | |||
| Shares Outstanding | 68.6 M | |||
| Shares Owned By Insiders | 4.60 % | |||
| Shares Owned By Institutions | 99.46 % | |||
| Number Of Shares Shorted | 3.89 M | |||
| Price To Earning | (32.69) X |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Other Consideration for investing in Alpine Stock
If you are still planning to invest in Alpine Immune Sciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Alpine Immune's history and understand the potential risks before investing.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |